Amgen, Inc. Hits New 52-Week High of $387.49, Showcasing Strong Performance

Amgen, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 387.49 on February 25, 2026. This achievement underscores the company's robust performance, particularly in the context of its 1-year performance, which stands at an impressive 26.13%, significantly outpacing the S&P 500's return of 12.95%. With a market capitalization of USD 202,016 million, Amgen is classified as a large-cap company. The stock exhibits a price-to-earnings (P/E) ratio of 21.00, reflecting its valuation relative to earnings. Additionally, the company offers a dividend yield of 1.90%, which may appeal to income-focused investors. Amgen's financial health is further highlighted by a return on equity of 100.80%, indicating efficient management of shareholder equity. The company's debt-to-equity ratio stands at 5.27, suggesting a conservative approach to leveraging. Overall, Amgen's recent performance and financial metrics position it favorably within the competitive landscape of the pharmaceuticals and biotechnology industry.